Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

Blood Cancer GIFs – Healthcare Animations

A collection of fun and educational GIFs to support people during Blood Cancer Awareness month.

The Good Ideas Group

Burden of Heart Failure – Healthcare Animation

The BriefDevelop a video that will create an emotional response and connection strong enough to inspire HCPs to consult with Heart Failure patients more proactively and promptly.The SolutionCreate an animation...

The Good Ideas Group

Watercolour Stories – HCP Animation

We have been developing an approach to combine illustration with animation to create a 'living painting' that could be used to build and progress a story. Here are the results...

The Good Ideas Group

North – Corporate Animation

We partnered with 'North' to create a fun and vibrant launch animation. North are a business consultancy that bring fresh perspectives to running a business and they wanted their brand...

The Good Ideas Group

Cholangiocarcinoma – Disease Awareness

BackgroundCholangiocarcinoma (CCA) is a rare type of bile duct cancer, and it’s the second most common primary liver cancer in the world. Unfortunately, patients with CCA historically have limited treatment...

The Good Ideas Group

- PMLiVE

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option

Patients will now be able to access immunotherapy at an earlier stage in their treatment journey

- PMLiVE

AstraZeneca’s Farxiga shows benefits for heart failure patients in phase 3 trial

The SGLT2 inhibitor improved symptom burden, physical limitations and quality of life

- PMLiVE

Eli Lilly set to launch Tempo Personalized Diabetes Management Platform

Users can use the app to log insulin doses, set reminders and access education resources

- PMLiVE

Creating the urgency and drive needed to tackle antimicrobial resistance

By Jamie Doggett

- PMLiVE

Pfizer’s multiple myeloma treatment granted FDA Breakthrough Therapy Designation

Elranatamab-treated patients achieved an overall response rate of 61% in a phase 2 trial

- PMLiVE

Lab-grown red blood cells used for human transfusions in world-first clinical trial

Manufactured blood cells could revolutionise treatments for people with blood disorders

- PMLiVE

Ionis reports positive phase 2b results for fesomersen in thrombosis prevention

The company also announced it will regain rights to the antisense medicine from Bayer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links